MetaCap

Qiagen N.V. (QGEN)

NYSE: QGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

49.30-0.33 (-0.66%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

QGEN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$10.18B
Dividend yield
0.71% ($0.35)
Ex-dividend date
Jul 7, 2026
52-week range
32.53 – 57.82
Day range
49.28 – 49.61
Volume / Avg
2.63M / 3.65M
Beta
—

52-week range

$32.53$57.82

QGEN stock today

Qiagen N.V. (QGEN) closed at $49.30 on Nov 20, down 0.66% (-$0.33), versus the S&P 500's 3.70% decline. Shares are 14.7% below their 52-week high of $57.82, set on Jan 20, 2026 and 51.6% above the 52-week low of $32.53, in the middle of the past year's range. QGEN is up 9.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 5.3%.

At 26.6x trailing earnings, Qiagen N.V. trades below the peer-group median of 42.0x. Its forward P/E of 18.5x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Qiagen N.V. pays an annual dividend of $0.35 per share, a 0.71% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About Qiagen N.V.

Company profile

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Jonathan M. Pratt
Headquarters
Venlo
Employees
5,400
IPO year
2026
Website
qiagen.com

Financial highlights

Full financials

In fiscal 2025, Qiagen N.V. generated $2.09 billion in revenue, up 5.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $424.9 million (+408.3% year over year), for a net margin of 20.3% versus a median of 19.2% in the prior 5 years. Gross margin was 62.2% (up from 48.9%) and operating margin 22.3%.

Qiagen N.V. annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$2.09B$1.98B$1.97B$2.14B$2.25B
Growth+5.65%+0.66%-8.23%-4.89%+20.39%
Net income$424.88M$83.59M$341.30M$423.21M$512.60M
EPS (diluted)$1.94$0.37$1.48$1.84$2.21

Analyst forecast

Forecast

Consensus (12 analysts)

hold

Avg. price target

$49.77+0.95%

  • Strong buy 1
  • Buy 0
  • Hold 11
  • Sell 0
  • Strong sell 0

Target range

Low $40.00High $53.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$0.64 vs $0.63
Surprise
+1.59%

Dividends

Dividend history
Annual dividend
$0.35
Last payment
$0.35
Ex-dividend date
Jul 7, 2026

QGEN news

All QGEN news

Qiagen N.V. peers

Health Care sector
QGEN peer companies
CompanyPrice% ChgMarket capCompare
HALOHalozyme Therapeutics Inc.91.35-1.82%$10.41Bvs QGEN
RGENRepligen Corporation163.81-3.81%$10.47Bvs QGEN
KYMRKymera Therapeutics Inc.115.31-3.42%$9.84Bvs QGEN
KRYSKrystal Biotech Inc.308.89-2.19%$9.15Bvs QGEN
TECHBio-Techne Corp72.67-0.04%$11.42Bvs QGEN
PCVXVaxcyte Inc.55.39-5.09%$8.77Bvs QGEN
CGONCG Oncology Inc.79.47-2.97%$7.10Bvs QGEN
TWSTTwist Bioscience Corporation103.32-7.44%$7.04Bvs QGEN

Indexes, lists and sector

Qiagen N.V. stock FAQ

What is Qiagen N.V.'s stock price today?

QGEN last traded at $49.30 as of Nov 20, 4:00 PM EST, down 0.66% on the day. Prices are delayed at least 15 minutes.

Does Qiagen N.V. pay a dividend?

Yes. Qiagen N.V. pays $0.35 per share annually, a 0.71% yield. The most recent dividend of $0.35 had an ex-dividend date of Jul 7, 2026.

What is QGEN's P/E ratio?

QGEN trades at a trailing P/E ratio of 26.65 and a forward P/E of 18.48, compared with a median of 42.0 for its closest peers.

Who is Qiagen N.V.'s CEO?

Mr. Jonathan M. Pratt is the chief executive officer of Qiagen N.V., which has about 5,400 employees.

Has QGEN ever split its stock?

Yes. The most recent QGEN stock split was a 962-for-1000 split on Jan 25, 2017, one of 3 splits on record.

What is the QGEN 52-week high?

The 52-week high for QGEN is $57.82 and the 52-week low is $32.53. The stock is currently 14.7% below its high.

Compare QGEN